108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血清 Podoplanin 水平升高与溃疡性结肠炎的疾病严重程度及炎症相关：一项横断面研究
Received 16 March 2025
Accepted for publication 9 September 2025
Published 18 September 2025 Volume 2025:18 Pages 12989—13000
DOI https://doi.org/10.2147/JIR.S528624
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Nadia Andrea Andreani
Xiaogang Huang,1 Caifang Tang2
1Department of Gastroenterology, Sijing Hospital, Shanghai, 201601, People’s Republic of China; 2Department of Nursing, Sijing Hospital, Shanghai, 201601, People’s Republic of China
Correspondence: Caifang Tang, Department of Nursing, Sijing Hospital, Songjiang District, No. 389, Sitong Road, Shanghai, 201601, People’s Republic of China, Tel +86-18917537805, Email 18917537805@163.com
Objective: Podoplanin is a transmembrane glycoprotein that is primarily expressed in lymphatic endothelial cells, fibroblasts, and certain epithelial cells. Although it has been implicated in various physiological and pathological processes, its role in ulcerative colitis (UC) remains unclear. This study aimed to investigate the association between serum podoplanin levels and disease severity in patients with UC, and its potential involvement in coagulation and inflammation in patients with UC.
Methods: This cross-sectional study compared serum podoplanin levels in patients with remission-UC (n = 115), active-UC (n = 94), and healthy controls (n = 150). Active-UC patients were further classified as mild (n = 37), moderate (n = 31), or severe (n = 26) based on their Mayo scores. Clinical, inflammatory, and coagulation markers were measured and analyzed using one-way ANOVA, ROC analysis, and Pearson’s correlation. Podoplanin expression in human tissues was examined using the BioGPS database (https://biogps.org/).
Results: Serum podoplanin levels were significantly elevated in patients with UC (n=209) compared to healthy controls (n=150), with higher levels observed in patients with moderate (n=31) and severe (n=26) disease than in those with mild UC (n=37). Correlation analysis revealed that serum podoplanin levels were positively associated with coagulation markers-platelet count (r=0.247, p< 0.001), erythrocyte sedimentation rate (ESR; r=0.695, p< 0.001), D-dimer (r=0.765, p< 0.001), and fibrinogen (r=0.490, p< 0.001) as well as inflammatory markers, including C-reactive protein (CRP; r=0.767, p< 0.001), interleukin-1beta (IL-1β; r=0.744, p< 0.001), interleukin-6 (IL-6; r=0.786, p< 0.001), interleukin-17A (IL-17A; r=0.788, p< 0.001), tumor necrosis factor-α (TNF-α; r=0.784, p< 0.001), and Mayo score (r=0.912, p< 0.001).
Conclusion: Elevated serum podoplanin levels are closely associated with disease activity, inflammation, and hypercoagulability in patients with UC, suggesting that it may serve as a reliable biomarker for monitoring disease severity and guiding clinical management.
Keywords: ulcerative colitis, severity, coagulation, inflammation, podoplanin
1Department of Gastroenterology, Sijing Hospital, Shanghai, 201601, People’s Republic of China; 2Department of Nursing, Sijing Hospital, Shanghai, 201601, People’s Republic of China
Correspondence: Caifang Tang, Department of Nursing, Sijing Hospital, Songjiang District, No. 389, Sitong Road, Shanghai, 201601, People’s Republic of China, Tel +86-18917537805, Email 18917537805@163.com
Objective: Podoplanin is a transmembrane glycoprotein that is primarily expressed in lymphatic endothelial cells, fibroblasts, and certain epithelial cells. Although it has been implicated in various physiological and pathological processes, its role in ulcerative colitis (UC) remains unclear. This study aimed to investigate the association between serum podoplanin levels and disease severity in patients with UC, and its potential involvement in coagulation and inflammation in patients with UC.
Methods: This cross-sectional study compared serum podoplanin levels in patients with remission-UC (n = 115), active-UC (n = 94), and healthy controls (n = 150). Active-UC patients were further classified as mild (n = 37), moderate (n = 31), or severe (n = 26) based on their Mayo scores. Clinical, inflammatory, and coagulation markers were measured and analyzed using one-way ANOVA, ROC analysis, and Pearson’s correlation. Podoplanin expression in human tissues was examined using the BioGPS database (https://biogps.org/).
Results: Serum podoplanin levels were significantly elevated in patients with UC (n=209) compared to healthy controls (n=150), with higher levels observed in patients with moderate (n=31) and severe (n=26) disease than in those with mild UC (n=37). Correlation analysis revealed that serum podoplanin levels were positively associated with coagulation markers-platelet count (r=0.247, p< 0.001), erythrocyte sedimentation rate (ESR; r=0.695, p< 0.001), D-dimer (r=0.765, p< 0.001), and fibrinogen (r=0.490, p< 0.001) as well as inflammatory markers, including C-reactive protein (CRP; r=0.767, p< 0.001), interleukin-1beta (IL-1β; r=0.744, p< 0.001), interleukin-6 (IL-6; r=0.786, p< 0.001), interleukin-17A (IL-17A; r=0.788, p< 0.001), tumor necrosis factor-α (TNF-α; r=0.784, p< 0.001), and Mayo score (r=0.912, p< 0.001).
Conclusion: Elevated serum podoplanin levels are closely associated with disease activity, inflammation, and hypercoagulability in patients with UC, suggesting that it may serve as a reliable biomarker for monitoring disease severity and guiding clinical management.
Keywords: ulcerative colitis, severity, coagulation, inflammation, podoplanin